Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators and an upgrade in its Mojo Grade from Hold to Buy. The micro-cap pharmaceutical company’s shares have gained 2.61% today, closing at ₹1,662.00, reflecting renewed investor confidence amid improving technical trends and strong relative performance against the broader market.

Fredun Pharmaceuticals Ltd is rated Buy by MarketsMOJO, with this rating last updated on 29 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Fredun Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a blend of bullish and bearish signals across key indicators. Despite a modest dip of 1.79% on 16 Mar 2026, the stock’s long-term performance remains robust, with a 1-year return of 143.07% significantly outpacing the Sensex’s 1.00% over the same period.

Fredun Pharmaceuticals Ltd has demonstrated a significant shift in price momentum, supported by a range of technical indicators signalling a bullish trend. With a notable 7.18% gain on the day and a recent upgrade from Hold to Buy by MarketsMOJO, the stock is attracting renewed investor interest amid a strong performance relative to the broader market.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 July 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 March 2026, providing investors with the latest insights into its performance and outlook.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Fredun Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a nuanced change in price momentum. Despite a recent decline in daily price, the stock maintains a bullish stance on several key moving averages and monthly indicators, signalling potential opportunities for investors amid a complex technical landscape.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Fredun Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid robust price gains and strong operational metrics, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.

Fredun Pharmaceuticals Ltd., a Mumbai-based pharmaceutical formulations manufacturer, delivered an impressive third-quarter performance for FY2026, posting net profit of ₹10.48 crores—an 11.13% sequential improvement and the highest quarterly profit in the company's recent history. The ₹922-crore market cap company demonstrated robust operational efficiency, with operating margins expanding to 16.47% from 15.56% in the previous quarter, signalling strengthening pricing power and cost management discipline.

Fredun Pharmaceuticals Ltd has demonstrated a notable shift in technical momentum, with key indicators signalling an increasingly bullish trend. The stock’s recent price action, combined with evolving technical parameters such as MACD, RSI, and moving averages, suggests a strengthening outlook for investors in the Pharmaceuticals & Biotechnology sector.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Fredun Pharmaceuticals Ltd is rated Buy by MarketsMOJO. This rating was last updated on 29 July 2025, reflecting a shift from a previous Hold stance. However, the analysis and financial metrics discussed here represent the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Fredun Pharmaceuticals Ltd is rated Buy by MarketsMOJO. This rating was last updated on 29 Jul 2025, reflecting a shift from the previous Hold status. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 January 2026, providing investors with the latest insights into its performance and outlook.

Fredun Pharmaceuticals has exhibited a notable shift in price momentum, reflecting a transition towards a more bullish technical outlook. Recent market data and technical indicators suggest evolving investor sentiment in the Pharmaceuticals & Biotechnology sector, with Fredun’s stock price advancing significantly in the context of broader market movements.